-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UoLUm9xfepME2b+e4vZgOxkmKF5I7JBg/cOMljZvOc3a5OLUGGXO2BVpZm7SUeQk
 julnoCN80tY4H7HxD1T6NA==

<SEC-DOCUMENT>0000950144-07-006625.txt : 20070717
<SEC-HEADER>0000950144-07-006625.hdr.sgml : 20070717
<ACCEPTANCE-DATETIME>20070717125343
ACCESSION NUMBER:		0000950144-07-006625
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070717
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070717
DATE AS OF CHANGE:		20070717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER & OFFICE EQUIPMENT [3570]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		07983459

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g08387e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549<BR>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): July&nbsp;17, 2007</B><BR>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Illinois<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;8.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Other Events</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;17, 2007 we issued a press release announcing the commencement of two new HIV/AIDS
vaccine human clinical trials. A copy of the press release is attached to this Current Report.
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press Release
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD>Dated:  July 17, 2007<BR>
<BR>
<BR>
</TD>
</TR><TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="right" style="font-size: 10pt"><!-- Folio -->2 of 5<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>g08387exv99.htm
<DESCRIPTION>EX-99 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g08387g0838700.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>AT THE COMPANY</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Donald Hildebrand / Jennifer Nelms<BR>
(404)&nbsp;727-0971

</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GeoVax Announces Start of 2 New HIV/AIDS Vaccine Human Trials</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA, Ga., 17 July&nbsp;2007 &#151; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology
company, announced an early start of 2 new AIDS vaccine clinical (human)&nbsp;trials. These FDA
compliant trials were previously scheduled to start later in 2007 and are the 3<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP> and
4<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> in a 4 clinical trial series intended to evaluate both human safety and immune
responses to GeoVax&#146;s HIV/AIDS vaccines.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s vaccines are designed to prevent Acquired Immunodeficiency Disease (&#147;AIDS&#148;) in humans
caused by the virus known as HIV-1 (Human Immunodeficiency Virus), by vaccinating individuals with
its DNA and MVA vaccines prior to infection with the virus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starting April&nbsp;2006, the 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> of these 4 human trials evaluated a low dose
(1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of the vaccine dose) vaccination program. Preliminary results from this blinded
trial demonstrated excellent vaccine safety and positive anti-HIV-1 immune responses to the vaccine
in 9 of 11 participants where 9 people received GeoVax HIV/AIDS vaccines and 2 received placebos.
All trial participants were normal healthy individuals. Final results will be compiled for later
public release.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The 2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> of 4 human trials, initiated September&nbsp;2006, was designed to evaluate results
from full dose administration of GeoVax HIV/AIDS vaccines. Recent data indicates excellent safety
in this full dose trial. Additional results from ancillary testing conducted at Emory University by
Dr.&nbsp;Harriet Robinson demonstrated positive anti-HIV-1 immune responses in the majority of vaccine
recipients. Official immune response data will be available later this year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Excellent results from the 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> and 2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> trial of this 4 trial series have
allowed the accelerated start of human trials #3 and #4. These trials began more than a month
earlier than originally anticipated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Due to exceptionally good results, GeoVax&#146;s scientific team believes its vaccine may perform
equally as well in trial #3 which administers fewer vaccine doses and trial #4 which utilizes only
GeoVax&#146;s MVA vaccine. &#147;Success in these trials could lead to a simpler vaccine regime making it
easier to vaccinate people,&#148; stated Dr.&nbsp;Harriet Robinson, PhD., GeoVax&#146;s Co-founder and Scientific
Advisory Board Chairperson.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Don Hildebrand, GeoVax CEO/President/Co-founder, commented, &#147;We are pleased with the results
obtained to date from our ongoing full dose vaccine human trial. The excellent vaccine safety
profile demonstrated was key to accelerating the start date of these new human trials.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->3 of 5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Equally important are the positive immune responses observed in people receiving only
1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of a dose of our vaccines. This is very encouraging news.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">These human trials, utilizing GeoVax&#146;s AIDS vaccines, are conducted by the HIV Vaccine Trials
Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded and supported by the National
Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to the
development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the clinical
evaluation of GeoVax&#146;s DNA and MVA vaccines was also funded and supported by the National
Institutes of Health and National Institute of Allergy and Infectious Diseases.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * * * * * * * * * * * *
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">About GeoVax Labs, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture,
license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency
Virus) and other infectious agents. GeoVax&#146;s vaccine technology is protected by 20 issued and
filed patent applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s DNA and Recombinant MVA HIV/AIDS vaccines:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Protected 22 of 23 (96%) non-human primates for over 3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years post-infection with an
AIDS causing virus &#151; 5 of 6 non-vaccinates controls died of AIDS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Are manufactured and tested under GMP/GLP &#151; EMEA and FDA guidelines</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Satisfactorily completed early Phase 1 human clinical trial for DNA HIV/AIDS vaccine</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Are currently in 2 ongoing human trials started in 2006 with positive immune responses
reported in the majority of vaccine recipients as well as good vaccine safety</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Recently began 2 additional human trials with a large Phase 2 trial in planning stages
for 2008</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more information, visit www.geovax.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>All statements in this news release, not statements of historical fact, are forward-looking
statements. These statements are based on expectations and assumptions as of the date of this
press release and are subject to numerous risks and uncertainties which could cause actual results
to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be determined
to be safe for use in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in humans, the
vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can
raise the required capital to complete development of its vaccines, there is development of
competitive products that may be more effective or easier to use than GeoVax&#146;s products, and other
factors over which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters discussed in this news
release are forward looking statements involving certain risks and</I>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->4 of 5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>uncertainties including, without limitations, risks detailed in the Companies Securities and
Exchange Commission filings and reports.</I>
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->5 of 5<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g08387g0838700.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g08387g0838700.gif
M1TE&.#EA2P$T`.8``$A":J*<LK:QPN'>Y8)]F>OI[HB"G8N&HCPV8\/`S9J4
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M0`@#-P8"+^/?Y_S\_+NVQOO[^[6RP/S[^X^(H@8",`<",?___R'Y!```````
M+`````!+`30```?_@'^"@X2%AH>(B8J+C(V.BFQ!<Y-?#`*/F)F:FYR=GI^@
MH:*CI)X$,WU],QX@I:ZOL+&RL[2UHQ03?GXW8[:^O\#!PJ4J(4X=R,G*R`]K
M)B\ET=(H)C#+U\AH*XEL<WU^,U$#P^3EYN>R*RXH.^WM`%43W[KT]?;W^/BI
M,PCN[EH1_J#(U8?.A2'H$BI<N-!"&0T:QB"P`:0BC13Y,FK<R/$>$!IJ<OF9
MX":BA2T,4ZI<&6I%AP8-+@29>0-51WO?U`#Y4@4(A3!`4MA04X4+%`1,?A!X
M@0`!@!\_/B"`<H.&#:!6*5"P"D2-GWE])M`A.(&@'QH`9M:`F:'-%)9P_^.R
M+!#`@`$M<]1XO5FO3Y4<%*24L!$$C)('`4[@@7'`@(4#`7SX6"('2X4>F+=8
M;J#CA`\%$@0<F.P"#^@8&TI\*9&#ZMB19>?9TPL$"@X#/JC(W<W[EYD,"1CH
MY?MU!HWC%%X04$+D`),>2$9L6<$!"0=:U:=/1\*'+(4G4:H<G_$UG]XJ!A*T
MR=.[O7M/`Y0`H*!&=D<@47+<X`*SP1$T*K%@Q3>JK$'",0TD`$447&0AA7TX
M59'6`N]5:.$A`ACP`1!\J7&#4%%X=@(5=^RQAUP5R#,2%!`4<L>+;YR@@`@M
MY/#%4!#J,@,%/UQQX8^[@>#"`1Z$85-&?:20`O\0.;SP@@[^.=&B>VO(HPH`
MC11PA!-+*,'`"T#,<&1Y-'CPPA4+7`?DFN?L,<`:#*BX41\T2)%###Y(H.:%
M<FQ`8`H!;%+`"0<@H-\,(M63P@5H;'$'FY#^\@8>3-RTI!1/G*%"(B`<H<>G
MH'[ZP`(]P.($J`\D@,D5NH3E1BA:/`%&"G2,J0L=!A01Z:ZQ#$&`#(AJE$J#
M-3B1`7N&Y+&"!R7(0$,J==@W@1H;O.5*`BFH"(0.CS920JLIM#`*"!F<P047
M*:1"SP1AM+#"E+S&ZPD(!%3!45E2*'&)(D+LD*BPJ\#QR@,VU'-`(SH\.Q(=
M9+PB`!\;2)'NNA-<H(#_O!AK<H`,>^4SP0R5&.!$`8J$$,<7.6ZDZBM\V#0!
M"HP,X8&5*:QA[2MD.*$$%#/41T\5%U"8\=")%,$$$"GK4M8-.4C0R`@SRS;!
M#1M8$<56Q]%0@@>X^+&R*Q4@\-4$06RJ2!&O]6%#$K4\@$(.&(G4QQ<-P$OT
MW2%`D71Q*4`1@B,CE"#W#'1XH(,B6%!@P]>N:(!H6+THHH"5$U#P2Q$H2$$'
M6'[HT,K=1$<P()(IW*`!!H]LL/E7=LJ!!",@-'"S*RR\-H$!B@SQA3QB/1!,
M&P"01R#9VX".,1I&)*V*%%(L@<D#2(^-@$)#M,"[#8JP^LT$)90JC`*S#E^"
M_]W&1[J!G#B-Y`86R&:)PE>JM,#&0@G0\%4*,2#20PL$SE!#.0G80+`*XKOR
M[2H`'-+'M(+PN4<(('J5$]HGME`!$EC0#+-#Q!W(@`4+SF\08I,'!5APB`RH
M:`)5$%H/*FC!(@Q@`$5H(0;(P$(/=JL0,;1@!<@P`O(1P@EAB(T?$&`V`[()
M`/_J"QT80+),!($@=-!"!C71A`!<@#Q?N8$)`I((,_`!(U^Q01E$0((_B"%;
MWV";(6J`"E4$X0\K4(`;L)BD'&0!C72(`@+0^)4P[(L00O#9!%*P`0FT[Q!%
M^`+\4L`X(_[H-?C@WNLT$81Y[*"(FX!`%VR`OE;1(/\,N"M$"&*@L+Y,#05L
MN($\PF&($02A55)0P`%R4!:<#))W4JB`$*`@)QI@@1`\0-HW@&"$<3#B#5+@
M7:`<N:9:WB-)3M.$`,*0BBA^P@2VND<*#C:(*\0C(Q]C@!;:"(0"=I,>_+!>
M$B,Y`S'\`0N<')NX!C&'7(AEF8Z(P]A,P,PU3>R9$_A@)C1`.6,.H@EQ$$_6
M%GH<&V3@#Q!@@L^2E`(4$($+A-L>$`@@B!$`@2`S2`$"?*`%)8'K`+P<21Q&
M0`@9B(0.7>E?"CQPA@VD8$QA(>$?A'#3L(0A(""H0:LFL`&6/L(`J*!#(_OY
MGB!D<VQ+;80/-E>0X@W"`IW_?*852#"`6@[R"1:@PAMX0``K)*H*K?A`>280
MA2YTX`\8",`&/OJ5#7@`%1\3PB`T$#T_W)0L*+!`&3-@`F#-XV/NA*,;5D=4
M$G0!C=Q[*":0VH<--)&I%H(!#=89%@]L0@.MFH%5!0&`FR3@!R*9`98*@802
MM'$"!X`#RKZ1@C08H@6OE<&`"@(S00AU>W18*P`N*X@W"'![,]"I()Z8"NZ-
M[F,PT(0!LK5:S%X(`5G5A64U,=7FJG$02$R!7L8[G/X10)`HP.0@^+#9D?`!
M!O2@00$.*0@.M("J`&``55GQ!S8DD[9C404%IO@'`WRTN<K]`PSB89^P=&%/
MC_AH_QA&:]WWO.&N$$K2X3(Q@!(TUPN%>$$*>+"`$IMX`7P(+0%2&]4_].!;
M([&"X'1Q@T0(89$,R)8N>K&#14I,1?@T1`[&EMQ"2$"5]"A("HR*"1/H@J,5
M_E$34/!4&1CT$4Y-10D$-@@\I,&'?TB`BH4GA08,0@@<&Z\]@N6'4!["#LXD
M`'/9]0<*-#<%$AB)+BJ0B,GQ+L%_N,,7AQ>&!8!9$4S(E@D('.7VL,"IG03"
M!9R0B1CH>`;I'<0()FD(,1>'`*T"@ID%88+LZB@7,]!`(FHGDC%`+Q5J`(`P
MU?"!#L1F`KI"A`X>-P%`_Z$!"@O+#?[8"!(8P`]6>`"3&_]]H0+4BZY#C4(F
MCG`#`E%`#XWPM"I6G(H;C/H/3LX'F_W`AU4SU@=_X&58=.R',/P!;6/+]2%T
MP+LB$^(-3TB4*N*`DD8T(`I2^`&7F<VF!2#@O^N2@@09`8$#G+`&;6"$MF?`
M;7!L&-RZJ(C&;<"%*\1A'C1(1`RH^@4>_"$.SM01%-[-:P<D8G<(+L03TA66
MD7QCGHI0P1.X`(!H$CQ2*LB`#-C]#1NTH(&+8$&P)Y"#!!Q:$!/G00WJH`L;
M'*X'4%C4$;:^]0@<0<%RPH$/'X`RE0IB`.R^WQK^L(72ZD(-,"`?!/@@2'L+
M`@;>"`L=TI8%0RO"!T]H`(5_'BG_`2A!<ZWRPP;XL(6G#R(#POL*'7#0AL8?
M8N*G/1(``C"$,W#S$!50Y#QB,(4I30$&\11+Y/Z@A=6%90,`4K#]1I("$5@+
M`E,P`21S>E6ZBD4'?+5G&*)+"`Y,X01D)/S="L`#%'C@IE\!@@<LD``(&P()
M3`@P/:P`@%"%Z@"A34"'*4<8!P3`^Z`26.M!^H+SZX$!05R8%<PPB!.TMR!K
M'T34^AB$3P5`UE+33H*P`DBT#Q?``4-P`<'U#0PP:FW@`D_@`2C``\LF"AB@
M!P\P>)Z0!Q7`9YX0`7JP`(P&%TT@*J-0`"1U`U*@-#:@`"N`!$^7.1BQ-S@Q
M`ZK"4^4Q_R<(@`53$#SK5`\H%'N#X%+?(`7R]@=)@%T=H0KNQ`%:8"5^0`%<
MU`&TU"HVX`4?L`$Y8`4:H"9F@(7E)@@?@(7HE@D04`9^``22]0D0$``QX`4;
ML`$?X".;@`$#8@5OP`EP,(8'P!X:@(7$!@L.@"CNU@,!T`7$U0D%H``*<'!2
M0!XWP`1EA`CXIB0TJ"CYIP/!<Q-O]`<X,(/W,`%2@`")^`<!L#FU9P@KH`18
M9$NUPCMVT`2OI#2D>&\;`#]2<`,O<`+?)@@-4!90I@`WE0*.AP@KD"U!T`2A
M$`*Y0`=60`$>\`&<@`88<7&:T``CX0%O`0#;1@L20!YO90038/\%I0@?:$``
M*/`"$F,%&Z``,""$@_`&,/`$&U`550`%^)B/^HB/##")+,`$6E@;^[B/&^`[
M*Q`<60`$]V@$?Q$%2J`;AE``6@`%-(`'AU``;L``-P`$80`%%/`7)<``'PD%
M,G`!%R`#^"@#%%"&A,`''O`%8'`&$:",AM``B&*1!7`^,V4!4E$#Q)<$#A"4
M#F`!26`!0ND`26`"%^`"33"41ND`Q!<!,(`""/`!`K,%,!`#+0`#)C<((5!U
M9%`$"<`&0S"52.$[/3"4$J`%1BD'@L`#01D`.,`H11"43ZE7OW:40=EO@F`%
M(]$">8`&5:`V:V"4+4("0PD!"S"4=OG_E-3W!P.@`T&```3@`"/``7A@`4]I
MF7^@`R89``X01"4@E`TC`$'Y2Y\``B*@``SP!3+`!6!P`0+0!`5@-T<@`@$@
M`?VQF[S9`&\U"+<I`AG0F[QI6U<E`A(`'!*P!"Z@"&:0`$%V"`$0``+0``M@
M`4L`(`*P!,29!@_`EX1@!S#08H*0`4AS`6!'5`P0)MDR`P4``C,V2"G@6F4Q
M2#B`"C_PA+4R$FH@!`%$.!@!`$W0!=.2`R!#"%_9!T!0!B>B`@8@G\81`$GP
M,=F23%80`BM@+R&%*`:`1+74!SG0``*@-\TX$HDE"*I$!TN``3"`$1[PH'W0
M`QS0!=\``P@0_Q:K%%S@``!#L`1T0"N]$P!S@"BU]#\R@&SQYU?)5`<:L`6X
M,`,G4`I4H`1,`!Y2D`42H`/PJ'R+P(V>]8@;0`(NP`1Q@`*<M`%@4!`EH`4B
M,(M0H`5$X`-WI08*<(NJI3I]P`=@$%(O$`7I\HHS=09!%@(!-@&]4"E]<`,M
MH$HE418TT`*@-@,+T`)G$03V$P8:8#]T\`2\-`%7P"$S$`3JY@<G^@=]M2X`
M\*`3,)XI4`<>\`.H\`7,!3(V$!9\T`9=$('(J(!](`4O$%PAYU)!L`0>X`=J
M$`.J.@8!,!(`T)ROP`%F0`)DT*<O$`-:X#U<F@BEY0%CP*$@<`!&8/\$,O!1
M/]H'"-`*/<!))#$(7N`'53`"?E);#4`!=6`"XAB%]C(!7`,.8)"('%`#JO0Q
M8Q`&;V<$B%(#M'0[?[`$V5(&\;`!&+`[0>`$FY4"(*`#0%`'!K!9,Q`"`_!1
M`B@((M"J`"`9]I0#.5`'Q+@`F[,!/Z`+#+`"B"(%5(!="%`!.A"N7X`H&W`!
M8L$`KD0G!2".#``"FQ4&=L`&9?$!N^-+O]`#3I"'V:JM[>9A=)`';A<%'K!9
M3"`/JU4`_#D($7"D-!``G$2*%R!>Q3H!6="V61`%>%`&>]<'1H`Z.(0`B/**
M0."V4'`&*#,#@1(`98%=,Z`#>&`_04``'X7_`E/P2H.$*#QJJG4P`79;8+F`
MGG^03'YP"A/0!9H47(G[52/P%7&0!K4*`.U:.0!0$Q]@5OV9!-E"`(FF!@+`
M`KF@:D,@-F(R`ZLWM0F!1.!`!P$``:5%`1E0K'[@LWU@!3I@`7+U,2^``<Z[
M.0[@LVJ@C-:+`X,)!ATP`!*P`!E(`K@P`5ST!V1P!1(0`1Y:`IME!1$P`$L`
M`QE0!74@!8<SKS6'`"O@.'V0!G&20G_P2C)@`"&1`Q'@N%9@50<0%NB)!DE%
M`&/Q4V8U`]XDBB<0)V'``Q9`!VK`!/93!6EPBQ,@N!.P=A%0%AIR%G"E"__#
M>K7TKKZ[$`*`"C/@_VU_`+R;Z`=7`"P3``1V0L"#Y`$W,#-UD`'6NP0@8%9A
MD`0"E`)!4`,R0`!?4*;V0P.Y5@#8!0014\,28%-D4P-'<05CX0%<AG(?\RJ@
MY0<8P`!^X0(N@`LVD`9<\*//-RU0]FY6RU&JR@`2D"U$11YJL`#R(`5_<%=&
MD``68*P$L%E`L`-S``[+6@<,\`<?8,?O$W(8@!%J4`,8,$YA\7DQG!`J>`/<
MU`598`4J*`5`4&`E4`4JF0,<8&E68`0Y0`"JG`$X(`784P0JR%%K``9A(`,E
MP`4F@+(>8`4Y4`:#4```4#HW0`%00`1AEA]5\P4H(`*YF#^"$`>(4@(LY?\#
MJIP`!Y="V"P%Z!D#8&`#-G`#?E`"5I4!H_P6)Y`"4I`K)0`%`,`\OCH%JCP]
MZKB#,"`%-)`!5\`%R,P%-R`#>)"+/E("4A`'(,`%4H`E\$HK4=`$,8`H,_!=
MH8P.&&`'&&!Z;[`"=C``=F`'`X@!(U``RK@%;+`"(]`$/5#2'$#2RG@''VU,
M(P`"FX8!*S``(*`"(R"U@S`$`X`!&%``=H`L++T"*Q#40U#23`8"<!`"WH,$
M)ST$'XTZ*O#1)Y($>/`PN>#.@\`!6]TB,VT'V_#44\`&)@T"$'#2I3("L3@$
M6V`'+,`!$.#338`!+%``=P#2FP("=E";'XT0<,1)!D4@!!'``&>Q`/35T9+-
M,N11%BIK`-:W$"R@8Q/0`KTXV:!="E?P##F``&=@>W"Q`F?P`3AP!@L7VK!-
/"A'``Y\-%U00<880"``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
